Tumor patients with EGFR19 gene mutation can have corresponding targeted drug treatment, EGFR and tumor growth and metastasis are related, EGFR gene mutation is the most important driver gene in lung cancer, and it is a predictive indicator for molecular targeted therapy. There are 18, 19, 20 and 21 loci in EGFR gene, and EGFR gene testing is more common in lung cancer patients with mutations at 19 and 21 loci. The effect of EGFR-TKI treatment in patients with EGFR19 locus mutation may be better than other EGFR gene mutation types, and the sensitivity and specific effect of mutations at different loci on the treatment with the corresponding targeted drugs may be different. Patients with EGFR gene mutations, specific treatment options, need to consult a professional doctor for guidance.